image
Healthcare - Drug Manufacturers - General - NYSE - US
$ 164.99
-2.74 %
$ 292 B
Market Cap
57.69
P/E
1. INTRINSIC VALUE

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic.[ Read More ]

The intrinsic value of one ABBV stock under the base case scenario is HIDDEN Compared to the current market price of 165 USD, AbbVie Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart ABBV

image
FINANCIALS
54.3 B REVENUE
-6.44%
12.8 B OPERATING INCOME
-29.59%
4.88 B NET INCOME
-58.78%
22.8 B OPERATING CASH FLOW
-8.44%
-2.01 B INVESTING CASH FLOW
-222.47%
-17.2 B FINANCING CASH FLOW
30.56%
14.5 B REVENUE
-0.01%
3.83 B OPERATING INCOME
-4.18%
1.56 B NET INCOME
15.00%
5.45 B OPERATING CASH FLOW
139.85%
-8.26 B INVESTING CASH FLOW
-649.18%
-3.07 B FINANCING CASH FLOW
49.61%
Balance Sheet Decomposition AbbVie Inc.
image
Current Assets 33 B
Cash & Short-Term Investments 12.8 B
Receivables 11.2 B
Other Current Assets 9.03 B
Non-Current Assets 102 B
Long-Term Investments 304 M
PP&E 4.99 B
Other Non-Current Assets 96.4 B
Current Liabilities 37.8 B
Accounts Payable 3.69 B
Short-Term Debt 7.19 B
Other Current Liabilities 27 B
Non-Current Liabilities 86.5 B
Long-Term Debt 53 B
Other Non-Current Liabilities 33.5 B
EFFICIENCY
Earnings Waterfall AbbVie Inc.
image
Revenue 54.3 B
Cost Of Revenue 8.78 B
Gross Profit 45.5 B
Operating Expenses 24.8 B
Operating Income 12.8 B
Other Expenses 7.87 B
Net Income 4.88 B
RATIOS
83.84% GROSS MARGIN
83.84%
23.49% OPERATING MARGIN
23.49%
8.95% NET MARGIN
8.95%
46.94% ROE
46.94%
3.61% ROA
3.61%
14.26% ROIC
14.26%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis AbbVie Inc.
image
Net Income 4.88 B
Depreciation & Amortization 8.7 B
Capital Expenditures -777 M
Stock-Based Compensation 747 M
Change in Working Capital 2.81 B
Others 7.91 B
Free Cash Flow 22.1 B
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets AbbVie Inc.
image
Wall Street analysts predict an average 1-year price target for ABBV of $201 , with forecasts ranging from a low of $175 to a high of $228 .
ABBV Lowest Price Target Wall Street Target
175 USD 6.07%
ABBV Average Price Target Wall Street Target
201 USD 21.54%
ABBV Highest Price Target Wall Street Target
228 USD 38.19%
4. DIVIDEND ANALYSIS
0.79% DIVIDEND YIELD
1.64 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership AbbVie Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
61.9 M USD 1
6-9 MONTHS
81.2 M USD 9
9-12 MONTHS
451 K USD 1
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
3 months ago
Aug 05, 2024
Sell 12.4 M USD
GONZALEZ RICHARD A
EXECUTIVE CHAIRMAN OF BOARD
- 66500
186.52 USD
4 months ago
Jul 17, 2024
Sell 49.5 M USD
GONZALEZ RICHARD A
EXECUTIVE CHAIRMAN OF BOARD
- 282845
175 USD
7 months ago
Mar 20, 2024
Sell 3.72 M USD
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
- 21082
176.3 USD
8 months ago
Mar 18, 2024
Sell 4.67 M USD
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
- 26110
178.85 USD
8 months ago
Mar 18, 2024
Sell 913 K USD
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
- 5099
179.03 USD
8 months ago
Mar 18, 2024
Sell 4.96 M USD
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
- 27740
178.69 USD
8 months ago
Mar 01, 2024
Sell 2.72 M USD
RICHMOND TIMOTHY J.
EVP, CHIEF HR OFFICER
- 15412
176.4 USD
8 months ago
Mar 01, 2024
Sell 5.38 M USD
RICHMOND TIMOTHY J.
EVP, CHIEF HR OFFICER
- 30288
177.71 USD
8 months ago
Mar 01, 2024
Sell 1.74 M USD
RICHMOND TIMOTHY J.
EVP, CHIEF HR OFFICER
- 9853
176.35 USD
8 months ago
Mar 01, 2024
Sell 3.58 M USD
RICHMOND TIMOTHY J.
EVP, CHIEF HR OFFICER
- 20127
177.71 USD
8 months ago
Feb 23, 2024
Sell 2.51 M USD
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
- 14140
177.44 USD
8 months ago
Feb 29, 2024
Sell 909 K USD
Buckbee Kevin K
SVP, CONTROLLER
- 5144
176.65 USD
8 months ago
Feb 29, 2024
Sell 3.8 M USD
Michael Robert A.
PRES & CHIEF OPERATING OFFICER
- 21560
176.44 USD
8 months ago
Feb 29, 2024
Sell 8.35 M USD
Michael Robert A.
PRES & CHIEF OPERATING OFFICER
- 47319
176.46 USD
8 months ago
Feb 29, 2024
Sell 1.15 M USD
Siatis Perry C
EVP, GC AND SECRETARY
- 6504
177.05 USD
8 months ago
Feb 29, 2024
Sell 603 K USD
Siatis Perry C
EVP, GC AND SECRETARY
- 3387
178.04 USD
8 months ago
Feb 28, 2024
Sell 24.6 M USD
GONZALEZ RICHARD A
CHAIRMAN OF THE BOARD AND CEO
- 138616
177.27 USD
8 months ago
Feb 23, 2024
Sell 2.44 M USD
Siatis Perry C
EVP, GC AND SECRETARY
- 13753
177.51 USD
8 months ago
Feb 21, 2024
Sell 9.18 M USD
SALEKI-GERHARDT AZITA
EVP, CHIEF OPERATIONS OFFICER
- 52870
173.71 USD
10 months ago
Dec 26, 2023
Sell 451 K USD
Donoghoe Nicholas
EVP, CHIEF BUS/STRAT OFFICER
- 2912
154.72 USD
1 year ago
Jul 31, 2023
Sell 2.76 M USD
GONZALEZ RICHARD A
CHAIRMAN OF THE BOARD AND CEO
- 18500
149.15 USD
1 year ago
Aug 01, 2023
Sell 8.91 M USD
GONZALEZ RICHARD A
CHAIRMAN OF THE BOARD AND CEO
- 60000
148.58 USD
1 year ago
Feb 17, 2023
Sell 936 K USD
AUSTIN ROXANNE S
Director
- 6222
150.5 USD
1 year ago
Apr 25, 2023
Sell 1.01 M USD
Sorg Elaine K.
SVP, US COMMERCIAL OPERATIONS
- 6130
165 USD
1 year ago
Apr 17, 2023
Sell 1.13 M USD
Sorg Elaine K.
SVP, US COMMERCIAL OPERATIONS
- 6999
161.64 USD
1 year ago
Apr 17, 2023
Sell 81 K USD
Sorg Elaine K.
SVP, US COMMERCIAL OPERATIONS
- 500
162.04 USD
1 year ago
Apr 03, 2023
Sell 2.4 M USD
Sorg Elaine K.
SVP, US COMMERCIAL OPERATIONS
- 15002
160.03 USD
1 year ago
Apr 03, 2023
Sell 563 K USD
Siatis Perry C
EVP, GC AND SECRETARY
- 3520
160 USD
1 year ago
Mar 13, 2023
Sell 3.32 M USD
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
- 21810
152.3 USD
1 year ago
Mar 13, 2023
Sell 4.77 M USD
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
- 31315
152.27 USD
1 year ago
Mar 01, 2023
Sell 2.33 M USD
Sorg Elaine K.
SVP, US COMMERCIAL OPERATIONS
- 15003
155 USD
1 year ago
Mar 01, 2023
Sell 1.73 M USD
Siatis Perry C
EVP, GC AND SECRETARY
- 11330
153.06 USD
1 year ago
Mar 01, 2023
Sell 123 K USD
Siatis Perry C
EVP, GC AND SECRETARY
- 805
153.38 USD
1 year ago
Mar 01, 2023
Sell 2.31 M USD
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
- 15092
153.06 USD
1 year ago
Mar 01, 2023
Sell 130 K USD
Reents Scott T
EVP, CHIEF FINANCIAL OFFICER
- 850
153.38 USD
1 year ago
Mar 01, 2023
Sell 4.18 M USD
SALEKI-GERHARDT AZITA
EVP, OPERATIONS
- 26990
155 USD
1 year ago
Mar 01, 2023
Sell 1.41 M USD
SALEKI-GERHARDT AZITA
EVP, OPERATIONS
- 9220
153.05 USD
1 year ago
Mar 01, 2023
Sell 120 K USD
SALEKI-GERHARDT AZITA
EVP, OPERATIONS
- 780
153.39 USD
1 year ago
Mar 01, 2023
Sell 4.19 M USD
RICHMOND TIMOTHY J.
EVP, CHIEF HR OFFICER
- 27395
153.0784 USD
1 year ago
Mar 01, 2023
Sell 2.57 M USD
RICHMOND TIMOTHY J.
EVP, CHIEF HR OFFICER
- 16746
153.62 USD
1 year ago
Feb 21, 2023
Sell 517 K USD
Siatis Perry C
EVP, GC AND SECRETARY
- 3431
150.73 USD
1 year ago
Feb 21, 2023
Sell 595 K USD
Siatis Perry C
EVP, GC AND SECRETARY
- 3933
151.29 USD
1 year ago
Feb 17, 2023
Sell 1.5 M USD
AUSTIN ROXANNE S
Director
- 10000
150.5 USD
1 year ago
Feb 21, 2023
Sell 846 K USD
Strom Carrie C
SVP & PRES GLOBAL ALLERG AESTH
- 5615
150.71 USD
1 year ago
Feb 21, 2023
Sell 1.18 M USD
Strom Carrie C
SVP & PRES GLOBAL ALLERG AESTH
- 7780
151.28 USD
1 year ago
Feb 21, 2023
Sell 985 K USD
Strom Carrie C
SVP & PRES GLOBAL ALLERG AESTH
- 6533
150.74 USD
1 year ago
Feb 21, 2023
Sell 1.16 M USD
Strom Carrie C
SVP & PRES GLOBAL ALLERG AESTH
- 7646
151.29 USD
1 year ago
Feb 21, 2023
Sell 85.5 K USD
Strom Carrie C
SVP & PRES GLOBAL ALLERG AESTH
- 567
150.78 USD
1 year ago
Feb 21, 2023
Sell 60.5 K USD
Strom Carrie C
SVP & PRES GLOBAL ALLERG AESTH
- 400
151.34 USD
1 year ago
Feb 17, 2023
Sell 2.12 M USD
SALEKI-GERHARDT AZITA
EVP, OPERATIONS
- 14246
149.13 USD
1 year ago
Feb 17, 2023
Sell 1.61 M USD
SALEKI-GERHARDT AZITA
EVP, OPERATIONS
- 10754
150.05 USD
1 year ago
Feb 21, 2023
Sell 1.04 M USD
Sorg Elaine K.
SVP, US COMMERCIAL OPERATIONS
- 6901
150.74 USD
1 year ago
Feb 21, 2023
Sell 1.27 M USD
Sorg Elaine K.
SVP, US COMMERCIAL OPERATIONS
- 8420
151.29 USD
1 year ago
Dec 12, 2022
Sell 6.42 M USD
RICHMOND TIMOTHY J.
director: EVP, CHIEF HR OFFICER
- 39295
163.39 USD
1 year ago
Dec 12, 2022
Sell 505 K USD
RICHMOND TIMOTHY J.
director: EVP, CHIEF HR OFFICER
- 3075
164.1 USD
2 years ago
May 23, 2022
Sell 1.76 M USD
SEVERINO MICHAEL
Vice Chairman
- 11605
151.53 USD
2 years ago
May 16, 2022
Sell 13 M USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 83960
155 USD
2 years ago
Mar 01, 2022
Sell 2.31 M USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 15733
146.8105 USD
2 years ago
Mar 01, 2022
Sell 763 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 5167
147.6015 USD
2 years ago
Mar 01, 2022
Sell 595 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 4000
148.706 USD
2 years ago
Mar 01, 2022
Sell 14.9 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 100
149.381 USD
2 years ago
May 16, 2022
Sell 326 K USD
SEVERINO MICHAEL
Vice Chairman
- 2100
155.27 USD
2 years ago
May 16, 2022
Sell 13 M USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 83960
155 USD
2 years ago
May 06, 2022
Sell 7.06 M USD
SEVERINO MICHAEL
Vice Chairman
- 47215
149.53 USD
2 years ago
Mar 24, 2022
Sell 4.41 M USD
Stewart Jeffrey Ryan
EVP, Chief Commercial Officer
- 27690
159.2046 USD
2 years ago
Mar 09, 2022
Sell 1.75 M USD
Durkin Brian L
VP, Controller
- 11682
150.0082 USD
2 years ago
Mar 09, 2022
Sell 1.04 M USD
Durkin Brian L
VP, Controller
- 6946
150.0008 USD
2 years ago
Mar 01, 2022
Sell 2.31 M USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 15733
146.8105 USD
2 years ago
Mar 01, 2022
Sell 763 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 5167
147.6015 USD
2 years ago
Mar 01, 2022
Sell 595 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 4000
148.706 USD
2 years ago
Mar 01, 2022
Sell 14.9 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 100
149.381 USD
2 years ago
Mar 01, 2022
Sell 826 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 5596
147.5369 USD
2 years ago
Mar 01, 2022
Sell 1.23 M USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 8303
148.6224 USD
2 years ago
Mar 01, 2022
Sell 164 K USD
Gosebruch Henry O
EVP, Chief Strategy Officer
- 1101
149.1441 USD
2 years ago
Mar 01, 2022
Sell 344 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 2333
147.5922 USD
2 years ago
Mar 01, 2022
Sell 513 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 3451
148.5897 USD
2 years ago
Mar 01, 2022
Sell 104 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 700
149.0729 USD
2 years ago
Mar 01, 2022
Sell 1.38 M USD
RICHMOND TIMOTHY J.
EVP, Chief HR Officer
- 9381
147.5235 USD
2 years ago
Mar 01, 2022
Sell 2.14 M USD
RICHMOND TIMOTHY J.
EVP, Chief HR Officer
- 14424
148.5854 USD
2 years ago
Mar 01, 2022
Sell 392 K USD
RICHMOND TIMOTHY J.
EVP, Chief HR Officer
- 2627
149.0883 USD
2 years ago
Mar 01, 2022
Sell 918 K USD
Stewart Jeffrey Ryan
EVP, Chief Commercial Officer
- 6229
147.4276 USD
2 years ago
Mar 01, 2022
Sell 1.88 M USD
Stewart Jeffrey Ryan
EVP, Chief Commercial Officer
- 12659
148.4935 USD
2 years ago
Mar 01, 2022
Sell 387 K USD
Stewart Jeffrey Ryan
EVP, Chief Commercial Officer
- 2600
149.0357 USD
2 years ago
Mar 01, 2022
Sell 1.76 M USD
Michael Robert A.
Vice Chairman
- 11932
147.4134 USD
2 years ago
Mar 01, 2022
Sell 4 M USD
Michael Robert A.
Vice Chairman
- 26937
148.4901 USD
2 years ago
Mar 01, 2022
Sell 631 K USD
Michael Robert A.
Vice Chairman
- 4236
149.0633 USD
2 years ago
Feb 07, 2022
Sell 338 K USD
Strom Carrie C
SVP & Pres Global Allerg Aesth
- 2396
141.17 USD
2 years ago
Dec 20, 2021
Sell 1.52 M USD
Durkin Brian L
VP, Controller
- 11790
128.51 USD
2 years ago
Dec 17, 2021
Sell 23.1 M USD
Schumacher Laura J
Vice Chairman
- 177556
130.2313 USD
2 years ago
Dec 17, 2021
Sell 537 K USD
Schumacher Laura J
Vice Chairman
- 4114
130.6099 USD
2 years ago
Dec 15, 2021
Sell 275 K USD
Stewart Jeffrey Ryan
EVP, Chief Commercial Officer
- 2152
128 USD
2 years ago
Dec 13, 2021
Sell 406 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 3229
125.85 USD
2 years ago
Dec 13, 2021
Sell 406 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 3229
125.85 USD
2 years ago
Dec 09, 2021
Sell 7.92 M USD
GONZALEZ RICHARD A
Chairman of the Board and CEO
- 64476
122.8012 USD
2 years ago
Dec 09, 2021
Sell 13.5 M USD
GONZALEZ RICHARD A
Chairman of the Board and CEO
- 109624
123.4758 USD
2 years ago
Dec 06, 2021
Sell 6.04 M USD
RICHMOND TIMOTHY J.
EVP, Chief HR Officer
- 50350
120 USD
3 years ago
Nov 02, 2021
Sell 2.34 M USD
AUSTIN ROXANNE S
Director
- 20000
117.1 USD
3 years ago
Nov 02, 2021
Sell 2.9 M USD
AUSTIN ROXANNE S
Director
- 25000
116.11 USD
3 years ago
Nov 02, 2021
Sell 789 K USD
AUSTIN ROXANNE S
Director
- 6844
115.23 USD
3 years ago
Nov 03, 2021
Sell 2.34 M USD
AUSTIN ROXANNE S
Director
- 20000
117.23 USD
3 years ago
Aug 23, 2021
Sell 607 K USD
Strom Carrie C
SVP & Pres Global Allerg Aesth
- 5057
120 USD
3 years ago
Aug 23, 2021
Sell 850 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 7080
120 USD
3 years ago
May 24, 2021
Sell 9.05 M USD
SALEKI-GERHARDT AZITA
EVP, Operations
- 77863
116.2431 USD
3 years ago
May 24, 2021
Sell 1.06 M USD
SALEKI-GERHARDT AZITA
EVP, Operations
- 9057
116.7049 USD
3 years ago
May 03, 2021
Sell 470 K USD
Strom Carrie C
SVP & Pres Global Allerg Aesth
- 4184
112.4 USD
3 years ago
Mar 01, 2021
Sell 2.12 M USD
RICHMOND TIMOTHY J.
EVP, Chief HR Officer
- 19514
108.5908 USD
3 years ago
Mar 01, 2021
Sell 458 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 4219
108.6052 USD
3 years ago
Mar 01, 2021
Sell 458 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 4221
108.6086 USD
3 years ago
Mar 01, 2021
Sell 18.4 M USD
GONZALEZ RICHARD A
Chairman of the Board and CEO
- 169482
108.6087 USD
3 years ago
Mar 01, 2021
Sell 69 K USD
GONZALEZ RICHARD A
Chairman of the Board and CEO
- 631
109.325 USD
3 years ago
Mar 01, 2021
Sell 1.5 M USD
Stewart Jeffrey Ryan
SVP, US Commercial Operations
- 13773
108.5875 USD
3 years ago
Feb 22, 2021
Sell 2.09 M USD
Sorg Elaine K.
SVP, US Commercial Operations
- 19995
104.71 USD
3 years ago
Feb 22, 2021
Sell 21.1 K USD
Sorg Elaine K.
SVP, US Commercial Operations
- 200
105.28 USD
7. News
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip? Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year. zacks.com - 1 day ago
Got $1,500 to Invest? AbbVie Just Proved the Bull Thesis for Its Stock The drugmaker has convincingly laid to rest the biggest threat to its top line. fool.com - 2 days ago
Final Trades: Bitcoin, Abbvie and Baker Hughes The Investment Committee reveals their final trades for today. youtube.com - 2 days ago
2 Dividend Stocks to Buy Hand Over Fist in November These companies have solid businesses and excellent dividend growth track records. fool.com - 2 days ago
AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations AbbVie Migraine Career Catalyst Award™ contest winners shared inspiring stories and professional goals, showcasing their triumphs over the challenges of living with migraine AbbVie, a leader in migraine treatment, is committed to addressing the impact of migraine in the workplace Nearly 40 million Americans are living with migraine, a debilitating neurological disease, and are more likely to call in sick due to symptoms associated with migraine.1-2 NORTH CHICAGO, Ill. , Nov. 14, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest designed to support the career aspirations of people living with migraine. prnewswire.com - 3 days ago
Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. AbbVie entered an option agreement with Aldeyra, potentially licensing reproxalap for global markets. Aldeyra conducted a Phase 3 trial, where reproxalap met its primary endpoint in DED patients. seekingalpha.com - 3 days ago
AbbVie's Schizophrenia Failure Disappoints But Analysts Show Confidence In Immunology Portfolio On Monday, AbbVie Inc ABBV stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia failed two Phase 2 trials. benzinga.com - 4 days ago
AbbVie's loss is Bristol Myers Squibb's gain - analyst Recent trial failures over at pharma giant AbbVie Inc have created a window of opportunity for competitor Bristol-Myers Squibb Co (NYSE:BMY, ETR:RM, OTC:BMYMP), is analysts at UBS are to be believed. AbbVie stock took a $38 billion hit on Monday after the company revealed that Phase 2 trials of its emraclidine schizophrenia treatment have failed to meet their primary endpoint objectives. proactiveinvestors.com - 4 days ago
AbbVie Stock Declines as Schizophrenia Studies Fail, BMY Gains ABBV stock tumbles 13% after two mid-stage schizophrenia studies on emraclidine fail to meet their primary endpoint. BMY stock rises. zacks.com - 4 days ago
AbbVie's disappointing schizophrenia drug trial bodes well for rival Bristol Myers, analysts say AbbVie's “pain” is Bristol Myers Squibb's “gain,” says Truist Securities analyst Srikripa Devarakonda. marketwatch.com - 5 days ago
Buy, Sell, Or Hold AbbVie Stock? AbbVie stock (NYSE: ABBV) was down 12% on Monday, November 11, after the company announced that two mid-stage clinical trials of its drug Emraclidine to treat schizophrenia failed to meet their primary goal. [1] Emraclidine was developed by Cerevel Therapeutics, which AbbVie acquired for around $9 billion earlier this year. forbes.com - 5 days ago
8. Profile Summary

AbbVie Inc. ABBV

image
COUNTRY US
INDUSTRY Drug Manufacturers - General
MARKET CAP $ 292 B
Dividend Yield 0.79%
Description AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Contact 1 North Waukegan Road, North Chicago, IL, 60064-6400 https://www.abbvie.com
IPO Date Jan. 2, 2013
Employees 50000
Officers Mr. Timothy J. Richmond Executive Vice President & Chief Human Resources Officer Mr. Jeffrey Ryan Stewart Executive Vice President & Chief Commercial Officer Dr. Azita Saleki-Gerhardt Ph.D. Executive Vice President & Chief Operating Officer Mr. Sanjay Narayan Senior Vice President, Chief Ethics, Compliance Officer & Allergan Aesthetic Legal Ms. Elizabeth Shea Senior Vice President of Investor Relations Mr. Richard A. Gonzalez Executive Chairman Mr. Robert A. Michael Chief Executive Officer & Director Dr. Roopal Thakkar M.D. Executive Vice President of Research and Development & Chief Scientific Officer Mr. Perry C. Siatis Executive Vice President, General Counsel & Secretary Mr. Scott T. Reents Executive Vice President & Chief Financial Officer